The association of inpatient blood utilization and diagnosis-related group weight: implications for risk-adjusted benchmarking.


Journal

Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360

Informations de publication

Date de publication:
07 2019
Historique:
received: 16 11 2018
revised: 05 04 2019
accepted: 08 04 2019
pubmed: 21 5 2019
medline: 28 5 2020
entrez: 21 5 2019
Statut: ppublish

Résumé

Risk-adjusted benchmarking could be useful to compare blood utilization between hospitals or individual groups, such as physicians, while accounting for differences in patient complexity. The aim of this study was to analyze the association of red blood cell (RBC) use and diagnosis-related group (DRG) weights across all inpatient hospital stays to determine the suitability of using DRGs for between-hospital risk-adjusted benchmarking. Specific hierarchical organizational units (surgical vs. nonsurgical patients, departments, and physicians) were also evaluated. We studied blood use among all adult inpatients, and within organizational units, over 4 years (May 2014 to March 2018) at an academic center. Number of RBCs transfused, all patient refined (APR)-DRGs, and other variables were captured over entire hospital stays. We used multilevel generalized linear modeling (zero-inflated negative binomial) to study the relationship between RBC utilization and APR-DRG. A total of 97,955 hospital stays were evaluated and the median APR-DRG weight was 1.2. The association of RBCs transfused and APR-DRG weight was statistically significant at all hierarchical levels (incidence rate ratio = 1.22; p < 0.001). The impact of APR-DRG on blood use, measured by the incidence rate ratio, demonstrated an association at the all-patient and surgical levels, at several department and physician levels, but not at the medical patient level. The relationship between RBCs transfused and APR-DRG varied across organizational units. Number of RBCs transfused was associated with APR-DRG weight at multiple hierarchical levels and could be used for risk-adjusted benchmarking in those contexts. The relationship between RBC use and APR-DRG varied across organizational units.

Sections du résumé

BACKGROUND
Risk-adjusted benchmarking could be useful to compare blood utilization between hospitals or individual groups, such as physicians, while accounting for differences in patient complexity. The aim of this study was to analyze the association of red blood cell (RBC) use and diagnosis-related group (DRG) weights across all inpatient hospital stays to determine the suitability of using DRGs for between-hospital risk-adjusted benchmarking. Specific hierarchical organizational units (surgical vs. nonsurgical patients, departments, and physicians) were also evaluated.
STUDY DESIGN AND METHODS
We studied blood use among all adult inpatients, and within organizational units, over 4 years (May 2014 to March 2018) at an academic center. Number of RBCs transfused, all patient refined (APR)-DRGs, and other variables were captured over entire hospital stays. We used multilevel generalized linear modeling (zero-inflated negative binomial) to study the relationship between RBC utilization and APR-DRG.
RESULTS
A total of 97,955 hospital stays were evaluated and the median APR-DRG weight was 1.2. The association of RBCs transfused and APR-DRG weight was statistically significant at all hierarchical levels (incidence rate ratio = 1.22; p < 0.001). The impact of APR-DRG on blood use, measured by the incidence rate ratio, demonstrated an association at the all-patient and surgical levels, at several department and physician levels, but not at the medical patient level. The relationship between RBCs transfused and APR-DRG varied across organizational units.
CONCLUSION
Number of RBCs transfused was associated with APR-DRG weight at multiple hierarchical levels and could be used for risk-adjusted benchmarking in those contexts. The relationship between RBC use and APR-DRG varied across organizational units.

Identifiants

pubmed: 31106447
doi: 10.1111/trf.15343
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2316-2323

Informations de copyright

© 2019 AABB.

Auteurs

Ryan A Metcalf (RA)

Department of Pathology, University of Utah, Salt Lake City, Utah.
ARUP Laboratories, Salt Lake City, Utah.

Sandra K White (SK)

Department of Pathology, University of Utah, Salt Lake City, Utah.

Scott Potter (S)

Department of Pathology, University of Utah, Salt Lake City, Utah.

Reed Barney (R)

Enterprise Data Warehouse, University of Utah, Salt Lake City, Utah.

Cheri Hunter (C)

Enterprise Data Warehouse, University of Utah, Salt Lake City, Utah.

Michael White (M)

Enterprise Data Warehouse, University of Utah, Salt Lake City, Utah.

Toby Enniss (T)

Department of Surgery, University of Utah, Salt Lake City, Utah.

Charles Galaviz (C)

Department of Anesthesiology, University of Utah, Salt Lake City, Utah.

Santosh Reddy (S)

Department of Medicine, University of Utah, Salt Lake City, Utah.

Nathan Wanner (N)

Department of Medicine, University of Utah, Salt Lake City, Utah.

Robert L Schmidt (RL)

Department of Pathology, University of Utah, Salt Lake City, Utah.
ARUP Laboratories, Salt Lake City, Utah.

Robert Blaylock (R)

Department of Pathology, University of Utah, Salt Lake City, Utah.
ARUP Laboratories, Salt Lake City, Utah.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH